Compare DRVN & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DRVN | BEAM |
|---|---|---|
| Founded | 1972 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Automotive Aftermarket | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.8B |
| IPO Year | 2021 | 2020 |
| Metric | DRVN | BEAM |
|---|---|---|
| Price | $15.66 | $27.60 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 14 |
| Target Price | $20.00 | ★ $46.00 |
| AVG Volume (30 Days) | 891.3K | ★ 2.2M |
| Earning Date | 02-24-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,439,296,000.00 | $55,701,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.27 | $23.55 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 18.60 | N/A |
| 52 Week Low | $13.44 | $13.53 |
| 52 Week High | $19.74 | $36.44 |
| Indicator | DRVN | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 52.78 | 44.45 |
| Support Level | $15.05 | $28.37 |
| Resistance Level | $16.30 | $32.26 |
| Average True Range (ATR) | 0.55 | 2.72 |
| MACD | -0.05 | -0.57 |
| Stochastic Oscillator | 49.25 | 1.83 |
Driven Brands Holdings Inc is an automotive services company in North America. Its platform provides high-quality services to an extensive range of retail and commercial customers. The company provides an extensive range of core consumer and commercial automotive needs, including paint, collision, glass, and repair services, as well as a variety of high-frequency services, such as oil changes and car washes. The company segments include: Maintenance, Car Wash, Paint, Collision & Glass, and Platform Services. It derives maximum revenue from Maintenance Segment. Geographically, the company operates into United States, Canada and Rest of the World.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.